We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current ABUS market cap is 490M. The company's latest EPS is USD -0.4059 and P/E is -6.73.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 5.95M | 6.25M | 6.69M | 5.01M | 4.45M |
| Operating Income | -17.81M | -22.56M | -17.41M | -18.66M | -21.56M |
| Net Income | -17.57M | -21.93M | -16.34M | -17.09M | -20.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 6.01M | 6.91M | 10.99M | 39.02M | 18.14M |
| Operating Income | -144.07M | -57.33M | -73.52M | -65.46M | -78.1M |
| Net Income | -153.72M | -75.87M | -88.39M | -69.46M | -72.85M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 203.8M | 195.42M | 191.22M | 176.82M | 158.64M |
| Total Liabilities | 58.28M | 58.57M | 47.31M | 42.13M | 39.3M |
| Total Equity | 145.52M | 136.85M | 143.92M | 134.69M | 119.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 105.54M | 137.08M | 204.49M | 195.42M | 144.4M |
| Total Liabilities | 32.79M | 35.11M | 35.05M | 58.57M | 38.38M |
| Total Equity | 72.74M | 101.97M | 169.44M | 136.85M | 106.02M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -18.37M | -35.36M | -27.3M | -46.86M | -68.64M |
| Investing | -87.62M | -74.94M | 16.68M | 18.12M | 28.55M |
| Financing | 20.73M | 31.81M | 20.42M | 25.16M | 26.84M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -71.01M | -51.44M | -67.53M | -35.36M | -85.94M |
| Investing | 28.34M | -14.91M | -12.68M | -74.94M | 50.77M |
| Financing | 37.46M | 86.75M | 137.24M | 31.81M | 30.65M |
| Market Cap | 490M |
| Price to Earnings Ratio | -6.73 |
| Price to Sales Ratio | 27 |
| Price to Cash Ratio | 18.65 |
| Price to Book Ratio | 4.62 |
| Dividend Yield | - |
| Shares Outstanding | 179.49M |
| Average Volume (1 week) | 824.26k |
| Average Volume (1 Month) | 2.19M |
| 52 Week Change | 4.19% |
| 52 Week High | 3.29 |
| 52 Week Low | 1.69 |
| Spread (Intraday) | 0.01 (0.37%) |
| Company Name | Arbutus Biopharma Corporation |
| Address |
100 burnaby, british columbia V5J 5J8 |
| Website | https://www.tekmirapharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
